Literature DB >> 18695640

Novel interactions between the 5-HT transporter, 5-HT1B receptors and Rho kinase in vivo and in pulmonary fibroblasts.

K M Mair1, M R MacLean, I Morecroft, Y Dempsie, T M Palmer.   

Abstract

BACKGROUND AND
PURPOSE: While the 5-HT and Rho-kinase (ROCK) pathways have been implicated in the development of pulmonary arterial hypertension (PAH), the nature of any interactions between them remain unclear. This study investigated a role for ROCK in 5-HT-regulated proliferative responses in lung fibroblasts in vivo and in vitro. EXPERIMENTAL APPROACH: PAH was examined in mice over-expressing human 5-HT transporters (SERT+), from which pulmonary artery fibroblasts (PFs) were isolated to assess ROCK expression. In vitro analysis of 5-HT signalling employed CCL39 hamster lung fibroblasts. KEY
RESULTS: ROCK inhibition ablated increased pulmonary remodelling and hypertension observed in SERT+ mice, and ROCK1/2 protein levels were elevated in SERT+ PFs. ROCK inhibition also reduced 5-HT-stimulated proliferation by suppressing MEK-stimulated ERK phosphorylation. While optimal 5-HT-stimulated proliferation required 5-HT(1B) and 5-HT(2A) receptors and SERT, receptor sensitivity to Y27632 was restricted to the 5-HT(1B) receptor. Also, while hypoxia-induced pulmonary vascular remodelling and hypertension were sensitive to Y27632 in WT and SERT+ animals, the proportions sensitive to ROCK inhibition were increased by SERT over-expression. CONCLUSIONS AND IMPLICATIONS: SERT over-expression increased ROCK-dependent pulmonary remodelling in normoxia and hypoxia and SERT over-expression was associated with elevated ROCK1/2 levels. ROCK also potentiated 5-HT(1B) receptor-stimulated ERK activation and proliferation in vitro by facilitating MEK-ERK interaction.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18695640      PMCID: PMC2579673          DOI: 10.1038/bjp.2008.310

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  48 in total

Review 1.  5-hydroxytryptamine and the pulmonary circulation: receptors, transporters and relevance to pulmonary arterial hypertension.

Authors:  M R MacLean; P Herve; S Eddahibi; S Adnot
Journal:  Br J Pharmacol       Date:  2000-09       Impact factor: 8.739

2.  Distribution of obstructive intimal lesions and their cellular phenotypes in chronic pulmonary hypertension. A morphometric and immunohistochemical study.

Authors:  E S Yi; H Kim; H Ahn; J Strother; T Morris; E Masliah; L A Hansen; K Park; P J Friedman
Journal:  Am J Respir Crit Care Med       Date:  2000-10       Impact factor: 21.405

Review 3.  The myofibroblast in wound healing and fibrocontractive diseases.

Authors:  G Gabbiani
Journal:  J Pathol       Date:  2003-07       Impact factor: 7.996

4.  Involvement of RhoA/Rho kinase signaling in pulmonary hypertension of the fawn-hooded rat.

Authors:  Tetsutaro Nagaoka; Sarah A Gebb; Vijaya Karoor; Noriyuki Homma; Kenneth G Morris; Ivan F McMurtry; Masahiko Oka
Journal:  J Appl Physiol (1985)       Date:  2005-12-01

5.  Contribution of the 5-HT(1B) receptor to hypoxia-induced pulmonary hypertension: converging evidence using 5-HT(1B)-receptor knockout mice and the 5-HT(1B/1D)-receptor antagonist GR127935.

Authors:  A Keegan; I Morecroft; D Smillie; M N Hicks; M R MacLean
Journal:  Circ Res       Date:  2001-12-07       Impact factor: 17.367

6.  Attenuated hypoxic pulmonary hypertension in mice lacking the 5-hydroxytryptamine transporter gene.

Authors:  S Eddahibi; N Hanoun; L Lanfumey; K P Lesch; B Raffestin; M Hamon; S Adnot
Journal:  J Clin Invest       Date:  2000-06       Impact factor: 14.808

7.  Molecular and functional analysis identifies ALK-1 as the predominant cause of pulmonary hypertension related to hereditary haemorrhagic telangiectasia.

Authors:  R E Harrison; J A Flanagan; M Sankelo; S A Abdalla; J Rowell; R D Machado; C G Elliott; I M Robbins; H Olschewski; V McLaughlin; E Gruenig; F Kermeen; M Halme; A Räisänen-Sokolowski; T Laitinen; N W Morrell; R C Trembath
Journal:  J Med Genet       Date:  2003-12       Impact factor: 6.318

8.  Serotonin transporter overexpression is responsible for pulmonary artery smooth muscle hyperplasia in primary pulmonary hypertension.

Authors:  S Eddahibi; M Humbert; E Fadel; B Raffestin; M Darmon; F Capron; G Simonneau; P Dartevelle; M Hamon; S Adnot
Journal:  J Clin Invest       Date:  2001-10       Impact factor: 14.808

9.  Long-term treatment with a Rho-kinase inhibitor improves monocrotaline-induced fatal pulmonary hypertension in rats.

Authors:  Kohtaro Abe; Hiroaki Shimokawa; Keiko Morikawa; Toyokazu Uwatoku; Keiji Oi; Yasuharu Matsumoto; Tsuyoshi Hattori; Yutaka Nakashima; Kozo Kaibuchi; Katsuo Sueishi; Akira Takeshit
Journal:  Circ Res       Date:  2003-12-11       Impact factor: 17.367

10.  Serotonylation of small GTPases is a signal transduction pathway that triggers platelet alpha-granule release.

Authors:  Diego J Walther; Jens-Uwe Peter; Sandra Winter; Markus Höltje; Nils Paulmann; Maik Grohmann; Jakob Vowinckel; Victor Alamo-Bethencourt; Claudia S Wilhelm; Gudrun Ahnert-Hilger; Michael Bader
Journal:  Cell       Date:  2003-12-26       Impact factor: 41.582

View more
  16 in total

Review 1.  Basic science of pulmonary arterial hypertension for clinicians: new concepts and experimental therapies.

Authors:  Stephen L Archer; E Kenneth Weir; Martin R Wilkins
Journal:  Circulation       Date:  2010-05-11       Impact factor: 29.690

Review 2.  Cellular Pathways Promoting Pulmonary Vascular Remodeling by Hypoxia.

Authors:  Larissa A Shimoda
Journal:  Physiology (Bethesda)       Date:  2020-07-01

3.  Pulmonary vascular effects of serotonin and selective serotonin reuptake inhibitors in the late-gestation ovine fetus.

Authors:  Cassidy Delaney; Jason Gien; Theresa R Grover; Gates Roe; Steven H Abman
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2011-09-09       Impact factor: 5.464

Review 4.  Mechanisms of hypoxic pulmonary vasoconstriction and their roles in pulmonary hypertension: new findings for an old problem.

Authors:  Jeremy P T Ward; Ivan F McMurtry
Journal:  Curr Opin Pharmacol       Date:  2009-03-16       Impact factor: 5.547

5.  Effect of chronic perinatal hypoxia on the role of rho-kinase in pulmonary artery contraction in newborn lambs.

Authors:  Arlin B Blood; Michael H Terry; Travis A Merritt; Demosthenes G Papamatheakis; Quintin Blood; Jonathon M Ross; Gordon G Power; Lawrence D Longo; Sean M Wilson
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2012-11-14       Impact factor: 3.619

Review 6.  Vascular remodeling in pulmonary hypertension.

Authors:  Larissa A Shimoda; Steven S Laurie
Journal:  J Mol Med (Berl)       Date:  2013-01-19       Impact factor: 4.599

7.  Rho kinase inhibitor fasudil reduces l-DOPA-induced dyskinesia in a rat model of Parkinson's disease.

Authors:  Andrea Lopez-Lopez; Carmen M Labandeira; Jose L Labandeira-Garcia; Ana Muñoz
Journal:  Br J Pharmacol       Date:  2020-11-03       Impact factor: 8.739

Review 8.  Lung Circulation.

Authors:  Karthik Suresh; Larissa A Shimoda
Journal:  Compr Physiol       Date:  2016-03-15       Impact factor: 9.090

9.  Serotonin contributes to high pulmonary vascular tone in a sheep model of persistent pulmonary hypertension of the newborn.

Authors:  Cassidy Delaney; Jason Gien; Gates Roe; Nicole Isenberg; Jenai Kailey; Steven H Abman
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2013-04-19       Impact factor: 5.464

10.  Treatment with the Kv7 potassium channel activator flupirtine is beneficial in two independent mouse models of pulmonary hypertension.

Authors:  I Morecroft; A Murray; M Nilsen; A M Gurney; M R MacLean
Journal:  Br J Pharmacol       Date:  2009-06-05       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.